Close
x
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c
  • SENSEX Feb 26 2021 09:58
    50,215.75 -823.56 (-1.61%)
  • NIFTY Feb 26 2021 10:04
    14,866.75 -230.60 (-1.53%)
  • SENSEX Feb 26 2021 09:58
    50,215.75 -823.56 (-1.61%)
  • NIFTY Feb 26 2021 10:04
    14,866.75 -230.60 (-1.53%)
  • Nasdaq Feb 26 2021 04:30
    13,119.43 -478.54 (-3.52%)
  • DJIA Feb 26 2021 04:30
    31,402.01 -559.85 (-1.75%)
  • S&P 500 Feb 26 2021 04:30
    3,829.34 -96.09 (-2.45%)
  • Hang Seng Feb 25 2021 02:10
    30,074.17 +355.93 ( +1.20%)
  • Crude Oil Feb 26 2021 09:58
    4,623.00 +1.00 ( +0.02%)
  • Gold Feb 26 2021 09:58
    46,258.00 +17.00 ( +0.04%)
  • Silver Feb 26 2021 09:58
    68,925.00 -351.00 (-0.51%)
  • Copper Feb 26 2021 09:53
    728.90 -1.35 (-0.18%)
  • Pound / Rupee Dec 23 2016 22:30
    102.24 +0.28 ( +0.27%)
  • Dollar / Rupee Dec 23 2016 22:30
    72.30 -0.08 (-0.11%)
  • Euro / Rupee Dec 23 2016 22:30
    87.86 -0.13 (-0.14%)
  • Yen / Rupee Dec 23 2016 22:30
    0.68 0.00 (-0.64%)

BSE Code : | NSE Symbol : | ISIN:| SECTOR : |

NSE BSE
 

Volume 280564

Prev. Close

Open Price

Bid Price (QTY)

Offer Price (QTY)

 

Today’s High/Low -

52 wk High/Low -

Key Stats

MARKET CAP (RS CR) 48.73
P/E 26.87
BOOK VALUE (RS) 23.3676281
DIV (%) 0
MARKET LOT 3000
EPS (TTM) 2.94
PRICE/BOOK 3.38074534830516
DIV YIELD.(%) 0
FACE VALUE (RS) 10
DELIVERABLES (%)
4

News & Announcements

01-Jan-2021

Earum Pharmaceuticals Ltd - Shareholder Meeting / Postal Ballot-Scrutinizers Report

01-Jan-2021

Earum Pharmaceuticals Ltd - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

05-Dec-2020

Earum Pharmaceuticals to conduct AGM

05-Dec-2020

Earum Pharmaceuticals Ltd - Fixes Book Closure for AGM

05-Dec-2020

Earum Pharmaceuticals to conduct AGM

06-Nov-2020

Earum Pharmaceuticals to hold board meeting

26-Jun-2020

Earum Pharmaceuticals to announce Quarterly Result

26-Dec-2019

Board of Earum Pharmaceuticals approves change in company secretary and appointment of director

Corporate Actions

Bonus
Splits
Dividends
Rights
Capital Structure
Book Closure
Board Meeting
AGM
EGM
 

Financials

Income Statement

Standalone
Consolidated
 

Peers Comparsion

Select Company Name BSE Code NSE Symbol
Alembic Ltd 506235 ALEMBICLTD
Alembic Pharmaceuticals Ltd 533573 APLLTD
Alkem Laboratories Ltd 539523 ALKEM
ANG Lifesciences India Ltd 540694
Anglo-French Drugs & Industries Ltd 40169
Astron Drugs & Industries Ltd 524206
Aurobindo Pharma Ltd 524804 AUROPHARMA
Bajaj Healthcare Ltd 539872
Bal Pharma Ltd 524824 BALPHARMA
Biocon Ltd 532523 BIOCON
Bombay Drugs & Pharma Ltd (Merged) 524512
Brooks Laboratories Ltd 533543 BROOKS
Cadila Healthcare Ltd 532321 CADILAHC
Cebon India Ltd 524272
Celestial Biolabs Ltd 532871 CELESTIAL
Cepham Organics Ltd 507756
Cian Healthcare Ltd 542678
Cipla Ltd 500087 CIPLA
Claris Lifesciences Ltd 533288
Concord Drugs Ltd 538965
Dee-Pharma Ltd 507722 DEEPHARMA
Dishman Carbogen Amcis Ltd 540701 DCAL
Dr Reddys Laboratories Ltd 500124 DRREDDY
Dr Sabharwals Manufacturing Labs Ltd 507743
Dr.Datsons Labs Ltd 533412 DRDATSONS
Druid Pharma Ltd 40430
Eupharma Laboratories Ltd 530409 EUPHARMLAB
FDC Ltd 531599 FDC
Glenmark Pharmaceuticals Ltd 532296 GLENMARK
Gufic BioSciences Ltd 509079 GUFICBIO
Hindustan Bio Sciences Ltd 532041
Hindustan Biotech Ltd 40162
Indoco Remedies Ltd 532612 INDOCO
Ind-Swift Laboratories Ltd 532305 INDSWFTLAB
IOL Chemicals & Pharmaceuticals Ltd 524164 IOLCP
Ipca Laboratories Ltd 524494 IPCALAB
J B Chemicals & Pharmaceuticals Ltd 506943 JBCHEPHARM
Jagsonpal Pharmaceuticals Ltd 507789 JAGSNPHARM
Jayant Vitamins Ltd 506518
Jupiter Bioscience Ltd 524826 JUPITER
KDL Biotech Ltd 532291 KOPDRUGS
Kopran Ltd 524280 KOPRAN
Kothari Phytochemicals & Industries Ltd 40136
Lasa Supergenerics Ltd 540702 LASA
Lupin Laboratories Ltd (Merged) 500258 LUPINLAB
Lyka Labs Ltd 500259 LYKALABS
Mangalam Drugs and Organics Ltd 532637 MANGALAM
Medico Remedies Ltd 540937
Mercury Phytochem Ltd 524498
Merind Ltd 506895 MARIND
Mesco Pharmaceuticals Ltd 500274 MESCOPHARM
Morepen Laboratories Ltd 500288 MOREPENLAB
Mylan Laboratories Ltd 524794 MATRIXLABS
Natco Pharma Ltd 524816 NATCOPHARM
Oriental Remedies & Herbals Ltd 526989
Ortin Laboratories Ltd 539287 ORTINLABSS
P C I Chemicals & Pharmaceuticals Ltd 524792
Pan Drugs Ltd 531440
Panacea Biotec Ltd 531349 PANACEABIO
Parnax Lab Ltd 506128
Phaarmasia Ltd 523620
Pharmaceutical Products of India Ltd 524113 PPIL
Piramal Enterprises Ltd 500302 PEL
Ranbaxy Laboratories Ltd (Merged) 500359 RANBAXY
RPG Life Sciences Ltd 532983 RPGLIFE
Saamya Biotech (India) Ltd 532905
Sakar Healthcare Ltd 538377 SAKAR
Sandoz (India) Ltd (Merged) 531990
Sharda Drugs & Industries Ltd 24206
Shree Ganesh Biotech India Ltd 539470
Shree Ganesh Remedies Ltd 540737
Siddhartha Pharmachem Ltd 532122
SMS Lifesciences India Ltd 540679 SMSLIFE
Socrus Bio Sciences Ltd 524719
SOL Pharmaceuticals Ltd 500393 SOLPHARMA
Solara Active Pharma Sciences Ltd 541540 SOLARA
Source Natural Foods & Herbal Supplements Ltd 531398
Strides Pharma Science Ltd 532531 STAR
Sumitra Pharmaceutical & Chemicals Ltd (Merged) 524133 SUMITRAPHA
Sun Pharmaceuticals Industries Ltd 524715 SUNPHARMA
Supriya Pharmaceuticals Ltd 524784
Surya Pharmaceutical Ltd 532516 SURYAPHARM
Suven Pharmaceuticals Ltd 543064 SUVENPHAR
Syngene International Ltd 539268 SYNGENE
Syschem (India) Ltd 531173
Themis Medicare Ltd 530199 THEMISMED
Titan Biotech Ltd 524717
Tonira Pharma Ltd(merged) 530155
Torrent Pharmaceuticals Ltd 500420 TORNTPHARM
Triochem Products Ltd 512101
TTK Healthcare Ltd 507747 TTKHLTCARE
Unichem Laboratories Ltd 506690 UNICHEMLAB
Unicorn Pharmaceuticals (India) Ltd 524334
Valencia Nutrition Ltd 542910
Vardhaman Laboratories Ltd 524796
Vikram Thermo (India) Ltd 530477
Vivimed Labs Ltd 532660 VIVIMEDLAB
Welcure Drugs & Pharmaceuticals Ltd 524661
Wintac Ltd 524758
Wockhardt Ltd 532300 WOCKPHARMA
Zillion Pharmachem Ltd 524476 ZILONPHARM
Zota Health Care Ltd 538426 ZOTA

Share Holding

Category No. of shares Percentage
Total Foreign 0 0.00
Total Institutions 0 0.00
Total Govt Holding 0 0.00
Total Non Promoter Corporate Holding 6000 0.10
Total Promoters 4319882 70.04
Total Public & others 1842028 29.86
Total 6167910 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

About Earum Pharmaceuticals Ltd

Earum Pharmaceuticals Limited was originally incorporated as a private limited company with the name 'Earum Pharmaceuticals Private Limited' onJuly 26, 2012. Further, pursuant to Special Resolution passed by the shareholders at the Extra Ordinary General Meeting held on January 10, 2019, the company was converted into a Public Limited Company and consequently the name of the Company was changed from 'Earum Pharmaceuticals Private Limited' to 'Earum Pharmaceuticals Limited' on January 23, 2019. Mr. Bhumishth Narendrabhai Patel and Mrs. Payal Bhumishth Patel were the initial subscribers to Memorandum of Association of the Company. The Company is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, anti-malarial drugs, anti-allergic & anti cold drugs, analgesic/ anti-pyretic & anti inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastro intestinal drugs, steroids, gynecology drugs, calcium, multivitamins, anti-oxidants and injections. At present, the company offers around 125 pharmaceutical formulation products, of which around 24 products are marketed under its own brand name, the manufacturing of which is outsourced by the company to third parties. Apart from pharmaceutical formulation products, the company also deals in trading of active pharmaceutical ingredients (API's) such as Levofloxacin Hemihdrate IP Albendazol IP, Amoxicillin Trihydrate IP etc.

Earum Pharmaceuticals Ltd Chairman Speech

Dear Stakeholder,

On behalf of our Directors and myself, it is my pleasure to greet all of you at 7 Annual General Meeting.

I take this opportunity to welcome all investor,Board Member During the year under review your Company has raised an amount of Rs. 6,65,28,000 (Rupees Six Crore Sixty Five Lacs Twenty Eight Only) and enlist itself on the SME Platform of the BSE Limited, giving me an opportunity to thank all the investors who put their con dence on the growth potential of the Company.

The year witnessed incremental sales of 30.28% over the previous year at Rs. 50,70,00,145 (Rupees Fifty Crore Seventy lacs One Hundred Ninety Forty Five Only). We are building a more agile and innovation-driven enterprise, with an aggressive growth approach, which can respond faster to changing consumer demand and market dynamics. At the same time, we remain committed to our core principles and values to make specialty medicines accessible and affordable to all.

Over the years, we have constantly innovated intermediates, organic and inorganic molecules and have niche pharmaceutical intermediates.

I am deeply thankful to all our stakeholders for their encouragement and support. In particular, I am grateful to our inherent strength - all our employees. I am extremely proud of them.

By order of the Board For
EARUM PHARMACEUTICALS LIMITED.
S/D
BHUMISHTH NARENDRABHAI PATEL
Managing Director and Chairman
DIN: 02516641
Place: Ahmedabad
Date: 29th August 2019

   

Earum Pharmaceuticals Ltd Company History

Earum Pharmaceuticals Limited was originally incorporated as a private limited company with the name 'Earum Pharmaceuticals Private Limited' onJuly 26, 2012. Further, pursuant to Special Resolution passed by the shareholders at the Extra Ordinary General Meeting held on January 10, 2019, the company was converted into a Public Limited Company and consequently the name of the Company was changed from 'Earum Pharmaceuticals Private Limited' to 'Earum Pharmaceuticals Limited' on January 23, 2019. Mr. Bhumishth Narendrabhai Patel and Mrs. Payal Bhumishth Patel were the initial subscribers to Memorandum of Association of the Company. The Company is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, anti-malarial drugs, anti-allergic & anti cold drugs, analgesic/ anti-pyretic & anti inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastro intestinal drugs, steroids, gynecology drugs, calcium, multivitamins, anti-oxidants and injections. At present, the company offers around 125 pharmaceutical formulation products, of which around 24 products are marketed under its own brand name, the manufacturing of which is outsourced by the company to third parties. Apart from pharmaceutical formulation products, the company also deals in trading of active pharmaceutical ingredients (API's) such as Levofloxacin Hemihdrate IP Albendazol IP, Amoxicillin Trihydrate IP etc.

Earum Pharmaceuticals Ltd Directors Reports

To

The Member,

Earum Pharmaceuticals Limited,

Dear Shareholder

The Directors have pleasure in presenting Seventh Annual General Meeting along with Audited Statement of Accounts of the Company for the year ended 31st March, 2019.

For the year ended For the year ended
Particulars 31 March 2019 (Rs) 31 March 2018 (Rs)
Sales 50,70,00,145 35,43,66,709
Other Income 5,33,951 40,98,721
Total Revenue 50,75,34,096 35,84,65,430
Less : Expenditure 47,50,90,992 33,95,13,887
Earning before interest, Dep. & Tax 3,24,43,104 1,89,51,543
Less; Depreciation 3,76,668 2,18,645
Earning before interest & Tax 3,20,66,436 1,87,32,898
Less : Interest 92,98,367 63,18,952
Pro t before Tax 2,27,68,069 1,24,13,945
Less: Provision for taxation 61,54,500 32,50,200
Less;Deferred tax Nil 22,613
Pro t After Tax 1,66,13,56z9 91,41,132
Prior period adjustment Nil NIL
Written of Assets as per companies Act 2013 NIL NIL
Earnings per share 53.83 29.62
1.Basic
2.Diluted 53.83 29.62

Operational Overview

Your Company delivered yet another year of consistent and pro table growth. During the year the company has earned total income of 50,75,34,096/- (Previous year ` 35,84,65,430). The Company continues to operate only in one segment i.e pharmaceuticals intermediates and there is no change in the nature of Business of the Company. After all the nancial adjustments, the company has earned a net profit after tax of 1, 66, 13,569/- (One Crore Sixty Six Lacs Thirteen Thousand Five Hundred Sixty Nine Only).

Dividend

This year company not issues any dividend to shareholder.

Reserves

The amount of profit 1,66,13,56 rupees is transferred to the Reserve and Surplus Account

Review of Business Operations and Future Prospects

The company has accumulated profits at the end of the Financial Year. In order to improve the performance further, the Company continues its focus on cost ef ciencies, improving product quality and developing capabilities for servicing the stringent requirements of customers.

Your Company has boosted its sales and thus the pro tability by increasing the production capacity by installing new machines for forward and backward integration. This has helped us to tap the big names in the industry and there after building up our customer range. Our focus is on optimal utilization of resources, less cost and more pro t.

Details of The Associates/ Joint Venture / Subsidiaries Companies

The company does not have holding or subsidiary companies during the year and no other company has become holding / subsidiary/ joint venture.

There are no significant and material orders passed by the regulators or courts or tribunals impacting the going concern status of the company and its future operation.

Share Capital Structure

The Issued, Subscribed and Paid-up equity share capital as on 31st March, 2019 was 30,85,650 divided into 3,08,565 shares of 10/- each.

Meetings of the Board

The Board met seven times during the nancial year. Details of meetings are given in the Corporate Governance Report annexed herewith and forms part of this report. The intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013

DIRECTORS, KEY MANAGERIAL PERSONNEL

DIRECTORS

During the year your Company has designated Mr.BHUMISHTH NARENDRABHAI PATEL (DIN- 02516641) as Chairman of the Board and Managing Director . Mrs. PAYAL BHUMISHTH PATEL (DIN 05300011) was appointed wholetime director and Mr.Narendrakumar Gangaramdas Patel (07017438) was appointed Non Executive Director with effect from March 5 ,2019 Mr.Hetarth Ashokkumar Patel (Din-07940476) and Mr.Alpesh Fatehsingh Purohit (Din-07389212) who meets the criteria of independence as specified in section 149 of the Companies Act, 2013 read with Schdule V and have given declaration to that effect were appointed as independent directors with effect from March 5 , 2019 for a period of five years.

(ii) KEY MANAGERIAL PERSONNEL

During the yaer pursuant to the provisions of Section 203 of the Act read with the rules made there under, board appointed following as whole time key managerial personnel of the Company: 1. Mr. Bhumishth Narendrabhai Patel (DIN 02516641)- Managing Director 2. Mrs. Payal Bhumishth Patel (05300011) Whole Time Director 3. Mrs. Payal Bhumishth Patel- Chief Financial Of cer; 4. Mr. Parsotam K Purohit Company Secretary and Compliance Of cer.

SUBSIDIARIES, ASSOCIATES AND JOINT VENTURE COMPANIES

Your Company is not having any subsidiary, associate or joint venture. Further during the nancial year under review, no company has become or ceased to be subsidiary, joint venture or associate of the Company

Public Deposit

The Company has not accepted any public deposit during the year under review and no amount against the same was outstanding at the end of the year.

Declaration by Independent Directors.

The Company has received necessary declarations from each Independent Director of the Company con rming that he/she met with the criteria of independence as laid out in sub-section (6) of Section 149 of the Companies Act, 2013 and under Regulation 16(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Diversity

A diverse Board enables efficient functioning through differences in perspective and skill, and also fosters differentiated thought processes at the back of varied industrial and management expertise, gender, knowledge and geographical background. The Company follows diverse Board structure.

Conservation Of Energy, Technology Absorption And Foreign Exchange Earnings And Outgo

As required under Section 134 (3) (m) of the Act read with Rule 8 of The Companies (Accounts) Rules, 2014, particulars relating to conservation of Energy, R & D, Technology absorption and Foreign Exchange earnings / outgo are separately provided in the annexure to the Directors' Report as Annexure - 1.

Dematerialization of Securities

Your Company's Equity shares are admitted in the System of Dematerialization by both the Depositories namely NSDL and CDSL. The Company has signed tripartite Agreement through Registrar and Share Transfer Agent M/s Big share Services Pvt. Ltd. The Investors are advised to take advantage of timely dematerialization of their securities. The ISIN allotted to your Company is INE060601015. Total Share dematerialized up to 31st March 2019 were which constitute 100% of total capital. Your Directors request all the shareholders to dematerialize their shareholding in the company as early as possible.

Health, Safety and Environment

Safety and occupational health responsibilities are integral to your Company's business process. Safety is a key performance indicator and your Company is committed to ensuring zero harm to its employees, to any person in the Company premises and to the community. The Company is continuously focusing on improved training, new initiatives and communications enhancing safety in the work place.Apart from safety initiatives, your Company is also focusing on environment protection policy.

The Company has obtained necessary approvals from concerned Government Department / Pollution Control Board.

Directors Retiring By Rotation

Mr. Narendrakumar Gangaramdas Patel shall retire by rotation at the ensuing Annual General Meeting as per provisions of Law. He is eligible for reappointment and has offered himself for directorship of the company. Your directors recommend for his reappointment.

Director's Responsibility Statement

Pursuant to the requirement under section 134(3) (C) of the Companies Act, 2013 with respect to Directors' Responsibility Statement, it is hereby con rmed that :

1 In the preparation of the annual accounts for the nancial year ended 31st March 2018 as far as possible and to the extent, if any, accounting standards mentioned by the auditors in their report as not complied with, all other applicable accounting standards have been followed along with proper explanation relating to material departure

2 The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the nancial year and profit and loss account of the Company for that period;

3 The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

4 The Directors have prepared the annual accounts on a going concern basis; and

5 The Directors have laid down internal nancial controls to be followed by the company and that such internal nancial controls are adequate and are operating effectively

The Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

CORPORATE GOVERNANCE

Your company believes that sound corporate Governance is critical for enhancing and retaining investor trust and your company always seeks to ensure that its performance goals are met accordingly. The company has established systems and procedures to ensure that its Board of Directors is well informed and well equipped to fulfill its overall responsibilities and to provide management with the strategic direction needed to create long term shareholders value. The company had adopted many ethical and transparent governance practices even before they were mandated by law. The company has always worked towards building trust with shareholders, employees, customers, suppliers and other stakeholders based on the principles of good corporate goverence. However since the securities of the Company are listed ar SME platform of BSE Limited pursuant to the SEBI (LODR) Regulations 2019 company is not required to attach report on Corporate Governance to the report of Directors.

MATERIAL CHANGES AND COMMITMENTS :

The Company had received the Listing approval on July 4 , 2019 by BSE Limited for 18, 48,000 Equity Shares allotted pursuant to Initial Public Offering.

So there is no committee during the year.

COMPLIANCE OF SECRETARIAL STANDARDS

The Board of Directors hereby con rms that all the applicable Secretarial Standards have been duly complied with during the year under review.

PARTICULARS OF EMPLOYEE

There is no employee drawing salary in excess of the limit as specified in the Act.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has zero tolerance towards any action on the part of any employee which may fall under the ambit of 'Sexual Harassment' at workplace, and is fully committed to uphold and maintain the dignity of every women employee working in the Company. The Company values the dignity of individuals and strives to provide a safe and respectable work environment to all its employees. The Company is committed to provide an environment, which is free of discrimination, intimidation and abuse. Pursuant to the Act Company has constituted compliance committee. Company has not received any complaint under the said Act during the year under review.

CAUTIONARY NOTE

The statements forming part of the Director's Report may contain certain forward looking remarks within the meaning of applicable securities laws and regulations. Many factors could cause the actual results., Performances or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward looking statements.

CORPORATE SOCIAL RESPONSIBILITY

Pursuant to Section 135 of the Act, provisions of Corporate Social Responsibility are not applicable to your Company as your Company has not earned net profit of r 5 crore or more during previous nancial year, neither it has the net worth of r 500 crores or more, nor the turnover of the Company was of r 1000 crores or more for the previous nancial year

RELATED PARTY TRANSACTIONS

During the yaer your Company has not entered into any material related party transactions as specified in Section 188 of the Act. Details of related party transactions as required under Accountng standard are reported in the explanatory notes to the nancial statements.

Green Initiative

As the Act permits paperless compliances and as a measure of green initiative, we appeal to all those members who have not registered their e-mail addresses so far are requested to register their e-mail address in respect of electronic holding with their concerned Depository Participants and/or with the Company.

Appreciation

Your Directors place on record their sincere appreciation for the valuable support and co-operation as received from Government Authorities, Financial Institutions, Banks and all stake holders during the year. Directors are also thankful for the support extended by Customers, Suppliers and contribution made by the employees at all level. Directors would also like to acknowledge continued patronage extended by Company's shareholders in its entire endeavor.

On Behalf Of the Board of Directors
For, Earum Pharmaceuticals Limited
S/D S/D
BHUMISHTH NARENDRABHAI PAYAL BHUMISHTH PATEL
Managing Director Whole Time Director
Din: 02516641 Din: 05300011

   

Earum Pharmaceuticals Ltd Company Background

Bhumishth Narendrabhai PatelBhumishth Narendrabhai Patel
Incorporation Year2012
Registered OfficeG1 Ground Floor VR Complex,Nr Sanathal Cross Rd SP RingRd
Ahmedabad,Gujarat-382210
Telephone91-79-48402525,Managing Director
Fax
Company SecretaryRonakkumar Narendrabhai Lalwani
AuditorJ M Patel & Bros
Face Value10
Market Lot3000
ListingBSE - SME,
RegistrarBigshare Services Pvt Ltd
1st Flr Bharat Tin W,Makwana Road Marol ,Andheri (East) ,Mumbai - 400059

Earum Pharmaceuticals Ltd Company Management

Director NameDirector DesignationYear
Bhumishth Narendrabhai PatelChairman & Managing Director2019
Payal Bhumishth PatelWhole Time Director & CFO2019
Hetarth Ashokkumar PatelIndependent Director2019
Bhavik Shantilal PatelAddtnl Independent Director2019
Ronakkumar Narendrabhai LalwaniCompany Secretary2019
Narendrakumar Gangaramdas PatelAddtnl Non-Executive Director2019

Earum Pharmaceuticals Ltd Listing Information

Earum Pharmaceuticals Ltd Finished Product

Product NameUnit Installed
Capacity
Production
Quantity
Sales
Quantity
Sales
Value
Sale of Products NA 00055.10884

Contact us Contact us